664 related articles for article (PubMed ID: 7594101)
1. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors.
Kleiman NS; Raizner AE; Jordan R; Wang AL; Norton D; Mace KF; Joshi A; Coller BS; Weisman HF
J Am Coll Cardiol; 1995 Dec; 26(7):1665-71. PubMed ID: 7594101
[TBL] [Abstract][Full Text] [Related]
2. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
Gawaz M; Ruf A; Pogatsa-Murray G; Dickfeld T; Rüdiger S; Taubitz W; Fischer J; Müller I; Meier D; Patscheke H; Schömig A
Thromb Haemost; 2000 Jun; 83(6):915-22. PubMed ID: 10896249
[TBL] [Abstract][Full Text] [Related]
3. c7E3 Fab inhibits low shear flow modulated platelet adhesion to endothelium and surface-absorbed fibrinogen by blocking platelet GP IIb/IIIa as well as endothelial vitronectin receptor--results from patients with acute myocardial infarction and healthy controls.
Reininger AJ; Agneskirchner J; Bode PA; Spannagl M; Wurzinger LJ
Thromb Haemost; 2000 Feb; 83(2):217-23. PubMed ID: 10739376
[TBL] [Abstract][Full Text] [Related]
4. Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Popma JJ; Satler LF
J Invasive Cardiol; 1994; 6 Suppl A():19A-28A; discussion 45A-50A. PubMed ID: 10155090
[TBL] [Abstract][Full Text] [Related]
5. Shear-induced platelet aggregation is inhibited by in vivo infusion of an anti-glycoprotein IIb/IIIa antibody fragment, c7E3 Fab, in patients undergoing coronary angioplasty.
Konstantopoulos K; Kamat SG; Schafer AI; Bañez EI; Jordan R; Kleiman NS; Hellums JD
Circulation; 1995 Mar; 91(5):1427-31. PubMed ID: 7867183
[TBL] [Abstract][Full Text] [Related]
6. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
7. Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa.
Turner NA; Moake JL; Kamat SG; Schafer AI; Kleiman NS; Jordan R; McIntire LV
Circulation; 1995 Mar; 91(5):1354-62. PubMed ID: 7867173
[TBL] [Abstract][Full Text] [Related]
8. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
[TBL] [Abstract][Full Text] [Related]
10. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Coller BS; Anderson K; Weisman HF
Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
[TBL] [Abstract][Full Text] [Related]
11. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
EPIC Investigators
N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
[TBL] [Abstract][Full Text] [Related]
12. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time.
Ammar T; Scudder LE; Coller BS
Circulation; 1997 Feb; 95(3):614-7. PubMed ID: 9024148
[TBL] [Abstract][Full Text] [Related]
13. Safety, inhibition of platelet aggregation and pharmacokinetics of Fab'2 fragments of the anti-glycoprotein IIb-IIIa monoclonal antibody FRaMon in high-risk coronary angioplasty.
Mazurov AV; Pevzner DV; Antonova OA; Byzova TV; Khaspekova SG; Semenov AV; Vlasik TN; Samko AN; Staroverov II; Ruda MY
Platelets; 2002 Dec; 13(8):465-77. PubMed ID: 12487780
[TBL] [Abstract][Full Text] [Related]
14. Occupancy of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion.
Quinn MJ; Murphy RT; Dooley M; Foley JB; Fitzgerald DJ
J Pharmacol Exp Ther; 2001 May; 297(2):496-500. PubMed ID: 11303035
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of abciximab during angioplasty: comparison to healthy subjects.
Abernethy DR; Pezzullo J; Mascelli MA; Frederick B; Kleiman NS; Freedman J
Clin Pharmacol Ther; 2002 Mar; 71(3):186-95. PubMed ID: 11907493
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometric observations on the in vivo use of Fab fragments of a chimaeric monoclonal antibody to platelet glycoprotein IIb-IIIa.
Christopoulos C; Mackie I; Lahiri A; Machin S
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):729-37. PubMed ID: 8292722
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Reverter JC; Béguin S; Kessels H; Kumar R; Hemker HC; Coller BS
J Clin Invest; 1996 Aug; 98(3):863-74. PubMed ID: 8698879
[TBL] [Abstract][Full Text] [Related]
18. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents.
Hézard N; Metz D; Nazeyrollas P; Droulle C; Elaerts J; Potron G; Nguyen P
Thromb Haemost; 2000 Apr; 83(4):540-4. PubMed ID: 10780313
[TBL] [Abstract][Full Text] [Related]
19. Chimeric 7E3 prevents carotid artery thrombosis in cynomolgus monkeys.
Rote WE; Nedelman MA; Mu DX; Manley PJ; Weisman H; Cunningham MR; Lucchesi BR
Stroke; 1994 Jun; 25(6):1223-32; discussion 1233. PubMed ID: 8202985
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
Matzdorff A; Voss R
Thromb Res; 2006; 117(3):307-14. PubMed ID: 15894353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
